Casirivimab/Imdevimab for Active COVID-19 Pneumonia Which Persisted for Nine Months in a Patient with Follicular Lymphoma during Anti-CD20 Therapy

• Published in: Japanese Journal of Infectious Diseases Vol. 75; no. 6; pp. 608 - 611
• Main Authors: Nagai, Hiroyuki, Saito, Makoto, Adachi, Eisuke, Sakai-Tagawa, Yuko, Yamayoshi, Seiya, Kiso, Maki, Kawamata, Toyotaka, Koga, Michiko, Kawaoka, Yoshihiro, Tsutsumi, Takeya, Yotsuyanagi, Hiroshi
• Format: Journal Article
• Language: English
• Published: Japan National Institute of Infectious Diseases 30.11.2022; Japan Science and Technology Agency
• Subjects: Antibodies; Antibodies, Viral; Antiviral agents; BNT162 Vaccine; casirivimab and imdevimab; CD20 antigen; Chronic infection; Computed tomography; Coronaviruses; COVID-19; COVID-19 Drug Treatment; Drug resistance; Humans; immunocompromised host; Immunocompromised hosts; Immunotherapy; Infections; Lymphoma; Lymphoma, Follicular - drug therapy; Lymphoma, Follicular - pathology; Monoclonal antibodies; mRNA; mRNA Vaccines; Mutation; Patients; Pneumonia; Polymerase chain reaction; prolonged viral shedding; Risk analysis; Risk factors; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Viral diseases; viral isolation; Viruses; COVID-19; casirivimab and imdevimab; viral isolation; immunocompromised host; prolonged viral shedding

Immunocompromised patients are more likely to develop severe COVID-19, and exhibit high mortality. It is also hypothesized that chronic infection in these patients can be a risk factor for developing new variants. We describe a patient with prolonged active infection of COVID-19 who became infected...